AstraZeneca has admitted that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions in lawsuits brought ...

A replacement for a key COVID-19 antibody drug that has been used to protect immunocompromised Americans could be available within months, executives for drugmaker AstraZeneca said Thursday ...

AstraZeneca Plc agreed to buy Icosavax Inc. for as much as $1.1 billion to gain a developer of innovative vaccines for respiratory viruses. Astra offered $15 in cash for each of Icosavax’s ...

JONATHAN NACKSTRAND / Contributor / Getty images AstraZeneca agreed to pay $1.1 billion for Icosavax to expand its reach into cutting-edge vaccine technology with Icosavax's innovative vaccine ...

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...

AstraZeneca’sAZN0.77%increase; green up pointing triangle longest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company tries to grab a slice of the booming ...

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory ...

WASHINGTON — AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through the year, the organization said. The exit is the group’s third in five months ...